Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic Alternatives
14. März 2023 16:30 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), today announced its decision to discontinue its ongoing Phase 1/2 clinical trials evaluating the safety and...
Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO GU Cancers Symposium
16. Februar 2023 07:30 ET
|
Bellicum Pharmaceuticals, Inc.
Biochemical and radiographic responses reported in first two cohorts of dose escalation in heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) patients PSA50 or greater...
CORRECTION -- Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31. Januar 2023 18:43 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- In a release issued earlier today by Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), please note that the total number of stock options should be 20,000, not...
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31. Januar 2023 16:36 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers Symposium
19. Januar 2023 07:30 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an...
Bellicum Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with Rimiducid
11. Dezember 2022 10:00 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Dec. 11, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced a poster...
Bellicum Reports Third Quarter 2022 Financial Results and Provides Operational Update
10. November 2022 16:05 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial...
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31. Oktober 2022 17:49 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
Bellicum Pharmaceuticals to Participate in the 2022 Cell & Gene Meeting on the Mesa
04. Oktober 2022 07:30 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick...
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03. Oktober 2022 16:05 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...